Literature DB >> 18262088

Radiotherapy for rectal cancer is associated with reduced serum testosterone and increased FSH and LH.

Kjersti Bruheim1, Johan Svartberg, Erik Carlsen, Svein Dueland, Egil Haug, Eva Skovlund, Kjell Magne Tveit, Marianne G Guren.   

Abstract

PURPOSE: It is known that scattered radiation to the testes during pelvic radiotherapy can affect fertility, but there is little knowledge on its effects on male sex hormones. The aim of this study was to determine whether radiotherapy for rectal cancer affects testosterone production. METHODS AND MATERIALS: All male patients who had received adjuvant radiotherapy for rectal cancer from 1993 to 2003 were identified from the Norwegian Rectal Cancer Registry. Patients treated with surgery alone were randomly selected from the same registry as control subjects. Serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), testosterone, and sex hormone binding globulin (SHBG) were analyzed, and free testosterone was calculated (N = 290). Information about the radiotherapy treatment was collected from the patient hospital charts.
RESULTS: Serum FSH was 3 times higher in the radiotherapy group than in the control group (median, 18.8 vs. 6.3 IU/L, p <0.001), and serum LH was 1.7 times higher (median, 7.5 vs. 4.5 IU/l, p <0.001). In the radiotherapy group, 27% of patients had testosterone levels below the reference range (8-35 nmol/L), compared with 10% of the nonirradiated patients (p <0.001). Irradiated patients had lower serum testosterone (mean, 11.1 vs. 13.4 nmol/L, p <0.001) and lower calculated free testosterone (mean, 214 vs. 235 pmol/L, p <0.05) than control subjects. Total testosterone, calculated free testosterone, and gonadotropins were related to the distance from the bony pelvic structures to the caudal field edge.
CONCLUSIONS: Increased serum levels of gonadotropins and subnormal serum levels of testosterone indicate that curative radiotherapy for rectal cancer can result in permanent testicular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18262088     DOI: 10.1016/j.ijrobp.2007.10.043

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Acute primary testicular failure due to radiotherapy increases risk of severe postoperative adverse events in rectal cancer patients.

Authors:  John Tapper; Stefan Arver; Torbjörn Holm; Matteo Bottai; Mikael Machado; Ravi Jasuja; Anna Martling; Christian Buchli
Journal:  Eur J Surg Oncol       Date:  2019-07-19       Impact factor: 4.424

2.  Testicular radiation dose after multimodal curative therapy for locally advanced rectal cancer. Influence on hormone levels, quality of life, and sexual functioning.

Authors:  S Hennies; H A Wolff; K Jung; M Rave-Fränk; J Gaedcke; M Ghadimi; C F Hess; H Becker; R M Hermann; H Christiansen
Journal:  Strahlenther Onkol       Date:  2012-08-11       Impact factor: 3.621

3.  Incorporating Reproductive Health in the Clinical Management of Early-Onset Colorectal Cancer.

Authors:  Andreana N Holowatyj; Cathy Eng; Mark A Lewis
Journal:  JCO Oncol Pract       Date:  2021-09-23

4.  Effect of radiotherapy for rectal cancer on ovarian androgen production.

Authors:  J Segelman; C Buchli; A Svanström Röjvall; P Matthiessen; S Arver; M Bottai; M Ahlberg; R Jasuja; A Flöter-Rådestad; A Martling
Journal:  Br J Surg       Date:  2018-09-12       Impact factor: 6.939

5.  Stereotactic body radiotherapy for organ-confined prostate cancer.

Authors:  Alan J Katz; Michael Santoro; Richard Ashley; Ferdinand Diblasio; Matthew Witten
Journal:  BMC Urol       Date:  2010-02-01       Impact factor: 2.264

6.  Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer.

Authors:  Eric K Oermann; Simeng Suy; Heather N Hanscom; Joy S Kim; Sue Lei; Xia Yu; Guowei Zhang; Brook Ennis; Joyann P Rohan; Nathaniel Piel; Benjamin A Sherer; Devin Borum; Viola J Chen; Gerald P Batipps; Nicholas L Constantinople; Stephen W Dejter; Gaurav Bandi; John Pahira; Kevin G McGeagh; Lucile Adams-Campbell; Reena Jha; Nancy A Dawson; Brian T Collins; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  J Hematol Oncol       Date:  2011-03-27       Impact factor: 17.388

7.  Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial.

Authors:  Wen-Hua Fan; Fu-Long Wang; Zhen-Hai Lu; Zhi-Zhong Pan; Li-Ren Li; Yuan-Hong Gao; Gong Chen; Xiao-Jun Wu; Pei-Rong Ding; Zhi-Fan Zeng; De-Sen Wan
Journal:  Chin J Cancer       Date:  2015-06-10

Review 8.  Hydrogen as a new class of radioprotective agent.

Authors:  Liren Qian; Jianliang Shen; Yunhai Chuai; Jianming Cai
Journal:  Int J Biol Sci       Date:  2013-09-14       Impact factor: 6.580

9.  Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408.

Authors:  R Charles Nichols; Chen Hu; Jean-Paul Bahary; Kenneth L Zeitzer; Luis Souhami; Mark H Leibenhaut; Marvin Rotman; Elizabeth M Gore; Alexander G Balogh; David McGowan; Jeff Michalski; Adam Raben; Shari Rudoler; Christopher U Jones; Howard Sandler
Journal:  Adv Radiat Oncol       Date:  2017-08-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.